Supportive Care in Cancer

, Volume 27, Issue 5, pp 1581–1582 | Cite as

Bendamustine and G-CSF support

  • Osamu ImatakiEmail author
  • Shumpei Uchida
  • Shigeyuki Yokokura
  • Makiko Uemura
  • Norimitsu Kadowaki
Letter to the editor


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Cerchione C, De Renzo A, Di Perna M, Della Pepa R, Pugliese N, Catalano L, Pane F, Picardi M (2017) Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer 25(3):839–845CrossRefGoogle Scholar
  2. 2.
    Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87(4):277–283CrossRefGoogle Scholar
  3. 3.
    Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, van der Jagt RH (2015) Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol 94(12):2025–2032CrossRefGoogle Scholar
  4. 4.
    Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 26(27):4473–4479CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Hematology, Department of Internal Medicine, Faculty of MedicineKagawa UniversityMiki-townJapan

Personalised recommendations